AI Medical Scribes Draw $1 Billion, Adoption Lags

Investors put at least $1 billion into ambient AI medical scribes in 2025. The tools draft clinical notes and can summarize histories, assign billing codes, and help place orders. Abridge, led by founder and CEO Shiv Rao, doubled its valuation to $5.3 billion within four months in 2025. Menlo Ventures called the category healthcare AI's first breakout category in its 2025 report; Menlo is invested in Heidi. The AMA's 2026 Physician AI Survey found adoption lags clinician enthusiasm. Babson College researcher Wiljeana Glover said formal procurement can take time. Rao described multi-executive sales to big groups via the CMO, CFO, and CIO and said clinic go-to-market can be very painful, making distribution channels key. WellSky chief medical officer Jamie Chang said the value prop and desire are there but more trust in the process may be needed, and that the industry continues to consolidate. WellSky now gives its AI scribe free to existing platform customers. A 2025 Stanford Health Care survey found 73.6% of 2,202 patients who experienced an AI scribe, after advance notice and a chance to decline, wanted it used again. A Canadian survey of 12,153 adults found 28.3% aware of the tools and 61.8% reluctant to have one used. No factual disputes appear in the record.